Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
about
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjectsEffects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazideIdentification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide eliminationPharmacogenetic studies update in type 2 diabetes mellitusPharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agentsIndividualized medicine enabled by genomics in Saudi ArabiaEffects of Clopidogrel and Proton Pump Inhibitors on Cardiovascular Events in Patients with Type 2 Diabetes Mellitus after Drug-Eluting Stent Implantation: A Nationwide Cohort StudyIndividualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data.Genetics of type 2 diabetes: insights into the pathogenesis and its clinical application.Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms.Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.Pharmacogenetics of Anti-Diabetes Drugs.The molecular mechanisms and pharmacotherapy of ATP-sensitive potassium channel gene mutations underlying neonatal diabetesFicus deltoidea: A Potential Alternative Medicine for Diabetes Mellitus.Variation in Association Between Thiazolidinediones and Heart Failure Across Ethnic Groups: Retrospective analysis of Large Healthcare Claims Databases in Six CountriesPharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine.No significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone.Can pharmacogenetics help rescue drugs withdrawn from the market?PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes.Nutrigenomics: concepts and applications to pharmacogenomics and clinical medicine.Pharmacogenetics of thiazolidinedione therapy.Cytochrome P450 reaction-phenotyping: an industrial perspective.Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.Interindividual variability of methadone response: impact of genetic polymorphism.PhRMA white paper on ADME pharmacogenomics.CYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patientsPharmacogenetics and personalized treatment of type 2 diabetesPolymorphisms of the KCNQ1 gene are associated with the therapeutic responses of sulfonylureas in Chinese patients with type 2 diabetes.Drug-induced liver injury: insights from genetic studies.Genetic polymorphisms in diabetes: influence on therapy with oral antidiabetics.CYP2C metabolism of oral antidiabetic drugs--impact on pharmacokinetics, drug interactions and pharmacogenetic aspects.The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs.Transporter-mediated drug-drug interactions with oral antidiabetic drugs.Pharmacotherapy of type 2 diabetes mellitus: an update on drug-drug interactions.Stratified medicine for the use of antidiabetic medication in treatment of type II diabetes and cancer: where do we go from here?Reaction phenotyping to assess victim drug-drug interaction risks.Using Personalized Medicine in the Management of Diabetes Mellitus.Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylurea-induced hypoglycaemia: A GoDARTS Study.
P2860
Q24564755-22D8FDAD-402A-475E-BAC5-942191FE8DEAQ24651117-4C9585B5-71D2-4808-8022-95DFDDE825B8Q24670563-41600E38-BF6A-4BB5-8F95-9F70E1A947C4Q26739350-63AD4B11-05F0-4DDF-A0D1-1E4FB693009FQ26751138-39856788-B6EE-43EA-8710-4670667282E3Q26861059-8A3315E1-93A4-4AEA-B6E6-47CFA2866144Q28547539-79658801-AD1D-4B2E-8875-E85FD11C4DF1Q30571118-F9E6D14F-B878-40BB-B3FD-B5669555075AQ30688345-B52710E7-889D-48B4-A5E3-7D226F76395DQ33593963-404B4043-79BF-41E7-8309-503C8579008AQ33813015-6C512D2B-FE2B-411D-BE51-A0983D1C8641Q33993320-913EBBA9-B1E1-4E57-9E43-57ED9B9DC1ABQ34181995-3B13BAE8-E5B4-401D-925F-B1CEC0509225Q34316689-4B34B17F-03CE-4D75-9D38-FD51576301FAQ36023341-A777187E-30FB-493A-BE1E-4E186AE51623Q36034337-E4ECF25F-8659-469B-9760-B9BF83471B86Q36441465-F7030979-79C4-4C2B-8FB7-B4D6E9839EBBQ36536042-7EEF6A0C-2466-41A7-8DDB-C2AE07C12AA3Q36596713-0C6B1FE6-2492-41FF-89AF-B2E03254D2E4Q36772391-2CAC6B9F-0EF4-4705-B5F5-3482E1D0DE13Q36772839-5FAFCF5F-CB60-496A-A30E-2D477D8284BFQ36918107-F16847B7-6945-45B0-A8B3-EBE9DB2662DAQ36960539-851DBADE-0712-4D5A-96EF-20557C21C6DDQ36986507-5B92281F-D437-4EED-84F9-5F8F53B8FEC3Q37142009-226BE535-85C7-4888-B781-C4BF151BE2F6Q37182212-76DFE54F-7E26-4731-8127-0C9B867C56E3Q37227417-68808B88-9839-4C7E-8FE3-71E2984C6076Q37508445-008821A3-E377-49BB-B504-64250167369AQ37571899-96A452C1-2F1F-4CDB-917D-B6E69808555AQ37598897-EABF1443-CCC3-44F4-BEF0-58234C141A6BQ37822185-0DE6193B-37EC-41F8-AB44-C5ECA5DFABC4Q38059889-001F4D20-0A3C-48FD-B458-1A992FF6484BQ38110432-68B46C15-D5F7-4199-A7FE-ACF7A4C3F2EBQ38168993-5463DFAA-A46B-4A77-A9EB-26B1DD643B5EQ38253580-33468337-C437-4B37-AA6B-22BBADDE15A2Q38270699-C7C9D63D-68DD-4C44-BC2A-CD1887296A18Q38640403-2937D2B2-2B09-4FE5-A487-BFF7B8442F94Q38666166-D570D33B-BE32-42D5-B6EB-94ACF7783DC1Q38684505-F36F8CB9-7F59-4433-8F77-9425EB5964E4Q38705682-BCC5EB96-42B2-4C80-9C59-B84DDB06A607
P2860
Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Effect of genetic polymorphism ...... tic drugs: clinical relevance.
@ast
Effect of genetic polymorphism ...... tic drugs: clinical relevance.
@en
type
label
Effect of genetic polymorphism ...... tic drugs: clinical relevance.
@ast
Effect of genetic polymorphism ...... tic drugs: clinical relevance.
@en
altLabel
Effect of Genetic Polymorphism ...... ics of Oral Antidiabetic Drugs
@en
prefLabel
Effect of genetic polymorphism ...... tic drugs: clinical relevance.
@ast
Effect of genetic polymorphism ...... tic drugs: clinical relevance.
@en
P2093
P2860
P1476
Effect of genetic polymorphism ...... tic drugs: clinical relevance.
@en
P2093
Bernd Rosenkranz
Ivar Roots
Julia Kirchheiner
Jürgen Brockmöller
Mark Goldammer
P2860
P304
P356
10.2165/00003088-200544120-00002
P577
2005-01-01T00:00:00Z
P6179
1045693053